SuperworthIridex profit margin IRIX
Gross, operating and net profit as a share of revenue over the last twelve months, from 2012.
- Net margin, 12 months
- −6.9%
- Operating margin, 12 months
- −5.4%
- Net margin on a year earlier
- +4.1 pts
- Peer median
- 4.9%
Over the twelve months to Jul 4, 2026, Iridex kept −6.9% of its revenue as net profit, with an operating margin of −5.4% and a gross margin of 35.9%.
Five years earlier its net margin was −5.4%.
The median for 7 healthcare stocks of a similar size is 4.9%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −8.4% | −4.9% | 36.5% |
| FY2024 | −18.3% | −17.1% | 40.1% |
| FY2023 | −18.5% | −19.3% | 42.0% |
| FY2022 | −13.2% | −13.2% | 44.5% |
| FY2021 | −9.7% | −14.0% | 42.4% |
| FY2020 | −17.4% | −18.1% | 42.8% |
| FY2019 | −20.3% | −20.7% | 41.3% |
| FY2018 | −30.1% | −30.2% | 41.0% |
| FY2017 | −30.9% | −31.0% | 37.3% |
| FY2016 | −25.4% | −5.6% | 45.1% |
| FY2015 | 1.1% | 0.7% | 47.8% |
| FY2014 | 23.4% | 6.0% | 50.0% |
| FY2013 | 5.8% | 6.9% | 48.6% |
| FY2012 | 4.2% | −2.5% | 48.3% |
| FY2011 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −6.9% | +4.1 pts | −5.4% | |
| Q1 FY26 | −6.2% | +8.4 pts | −5.1% | |
| Q4 FY25 | −8.4% | +9.9 pts | −4.9% | |
| Q3 FY25 | −10.0% | +12.7 pts | −6.0% | |
| Q2 FY25 | −11.0% | +10.9 pts | −7.1% | |
| Q1 FY25 | −14.6% | +7.3 pts | −10.7% | |
| Q4 FY24 | −18.3% | +0.1 pts | −17.1% | |
| Q3 FY24 | −22.8% | −8.6 pts | −22.5% | |
| Q2 FY24 | −21.8% | −8.1 pts | −21.5% | |
| Q1 FY24 | −21.9% | −9.3 pts | −21.9% | |
| Q4 FY23 | −18.5% | −5.2 pts | −19.3% | |
| Q3 FY23 | −14.2% | +1.3 pts | −15.3% |
Against its peers
Companies in Healthcare nearest Iridex's size, closest first, today.
| Company | Profit margin |
|---|---|
| IRIXIridex | −6.9% |
| NEPHNephros | 8.4% |
| ATNMActinium Pharmaceuticals | n/m |
| APTAlpha Pro Tech | 6.8% |
| SPROSpero Therapeutics | 15.7% |
| LFVNLifevantage | 2.8% |
| ICCCImmucell | 2.6% |
| KEQUKewaunee Scientific | 3.0% |
| Peer median | 4.9% |
Where Iridex ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Iridex
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.